We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Genetic Basis for Vulnerability to Substance Abuse

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00247819
First Posted: November 2, 2005
Last Update Posted: January 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
This investigation seeks to better define the genetic basis for vulnerability to substance abuse.

Condition Intervention
Substance Abuse Procedure: Blood draw

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Allelic Linkage in Substance Abuse

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 8000
Study Start Date: August 1992
Study Completion Date: February 2006
Primary Completion Date: February 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study.

This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Substance abusers
  • Allow for blood draw

Exclusion Criteria:

  • Cognitively impaired
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00247819


Locations
United States, Maryland
National Institute on Drug Abuse
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: George Uhl, M.D., Ph.D. National Institute on Drug Abuse (NIDA)
  More Information

Publications:
Gelernter J, Moises H, Grandy D, et al. Exclusion of schizophrenia triat from regions of the D2 dopamine receptor and prophobilinogen deaminase genes. In: 28th Annual Meeting, American College of Neurophyschopharmacology, December 13, 1980; Maui, Hawaii, Abstracts p.216.
Wyatt RJ, Farouk K, Suddath R, Hitri A. The role of dopamine in cocaine use and abuse. Psychiatric Annals 1988; 18:531-534.

ClinicalTrials.gov Identifier: NCT00247819     History of Changes
Other Study ID Numbers: NIDA-IRP-148
First Submitted: October 31, 2005
First Posted: November 2, 2005
Last Update Posted: January 12, 2017
Last Verified: October 2005

Keywords provided by National Institute on Drug Abuse (NIDA):
Substance abuse

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders